series-b
Stage
2021
Founded
2
Investors
About
Neumirna Therapeutics develops microRNA (miRNA)-based therapies that target root causes of neurological diseases to restore healthy neural network function, with programs focused on conditions such as epilepsy and Parkinson’s disease.
Explore NeUmiRNa Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.